Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Commission predicts issuing recast proposals in early 2012; key EU committee created

This article was originally published in RAJ Devices

Executive Summary

European Commission proposals for the recast of the EU directives on medical devices, active implantable medical devices and in vitro diagnostics could be finalised by the beginning of 20121. In the meantime, another endeavour to have emerged from the recast deliberations has taken a step forward, after member states set up a Central Management Committee (CMC) that they envisage will support the resources-challenged commission in ensuring consistency in the implementation of the legal requirements throughout the EU.

You may also be interested in...



Canada Introduces eCTD To Ease Clinical Trial Filings

Filing for clinical trial activities in the electronic common technical document format via the Common Electronic Submission Gateway is expected to help sponsors send their information in a secure manner, with reduced transmission times and cost.

Alexion Win Thwarts Roche’s EU Fast-Track Hopes

Roche hopes that its investigational drug satralizumab for neuromyelitis optica spectrum disorder will win EU approval in the second half of 2020.

New EU Approvals

The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with three new products including Novartis's Beovu for treating neovascular (wet) age related macular degeneration. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

UsernamePublicRestriction

Register

SC096327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel